Proteomics in Small Cell Lung Cancer
SCLC-OMICS
Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer
1 other identifier
observational
50
1 country
1
Brief Summary
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2022
CompletedFirst Posted
Study publicly available on registry
November 21, 2022
CompletedStudy Start
First participant enrolled
March 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedJanuary 31, 2025
August 1, 2024
2.8 years
November 14, 2022
January 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Identification and validation of protein biomarkers
For identification and validation of protein biomarkers both untargeted and targeted proteomics will be performed, including a discovery-based bottom-up mass spectrometry approach and label-free Quantification Nano Liquid Chromatography Tandem Mass Spectrometry (LFQ nLC-MS/MS), enzyme-linked immunosorbent assay (ELISA)-based proteomics, and Western Blot analyses.
3 years
Eligibility Criteria
The study will include 50 patients with newly diagnosed SCLC, referred to systemic antineoplastic treatment at the Dept. of Oncology, Aalborg University Hospital.
You may qualify if:
- Written and signed informed consent
- Histopathologically and/or cytologically newly-diagnosed SCLC
- Measurable disease on CT scans
- Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
You may not qualify if:
- Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
- Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
- Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
- Treatment with any other investigational agent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aalborg University Hospital
Aalborg, Region North Jutland, 9000, Denmark
Biospecimen
Blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Weronika Szejniuk, MD, PhD
Aalborg University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
November 14, 2022
First Posted
November 21, 2022
Study Start
March 1, 2023
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
January 31, 2025
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share